The anticancer properties of statins;Włas̈ciwos̈ci przeciwnowotworowe statyn

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 62, Issue , 2008, Pages 393-404

  Sławińska, Adrianna ^a   Kandefer Szerszeń, Martyna ^b  

^a MARIA CURIE SK ODOWSKA UNIVERSITY   (Poland)

^b Zakład Wirusologii i Immunologii Instytutu Mikrobiologii i Biotechnologii UMCS ^*  (Poland)

Author keywords

Angiogenesis; Apoptosis; Metastasis; Statins cancer

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; TERPENE;

ANIMAL; CHEMISTRY; DRUG ANTAGONISM; HUMAN; NEOPLASM; REVIEW; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MEVALONIC ACID; NEOPLASMS; TERPENES;

EID: 79953663485     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: None     Document Type: Article

References (110)

1. Agarwal B., Bhendwal S., Halmos B., Moss S.F., Ramey W.G., Holt P.R.: Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin. Cancer Res., 1999; 5: 2223-2229
2. Alarcón J., Águila S., Aranciba-Avila P., Fuentes O., Zamorano-Ponce E., Hernandez M.: Production and purification of rtatins from Pleurotus ostreatus Basidiomycetes strains. Zeitschrift für Naturforschung, 2003; 58: 62-64
3. Alberts A.W.: Discovery, biochemistry and biology of lovastatin. Am. J. Cardiol., 1988; 62: 10J-15J
4. Alonso D.F., Farina H.G., Skilton G., Gabri M.R., De Lorenzo M.S., Gomez D.E.: Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Res. Treat., 1998; 50: 83-93
5. Arnaud C., Braunersreuther V., Mach F.: Toward immunomodulatory and anti-inflammatory prope rties of statins. Trends Cardiovasc. Med., 2005; 15: 202-206
6. Bellosta S., Via D., Canavesi M., Pfister P., Fumagalli R., Paoletti R., Bernini F.: HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler. Thromb. Vasc. Biol., 1998; 18: 1671-1678
7. Brower V.: News of cancer and cholesterol: Studies elucidate anticancer mechanisms of statins. J. Natl. Cancer Inst., 2003; 95: 844-846
8. Burda P. Aebi M.: The dolichol pathway of N-linked glycosylation. Biochim. Biophys. Acta, 1999; 1426: 239-257
9. Cafforio P., Dammacco F., Gernone A., Silvestris F.: Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis, 2005; 26: 883-891
10. Chang C., Werb Z.: The many faces of metalloproteinases: cell growth, invasion, angogenesis and metastasis. Trends Cell Biol., 2001; 11: S37-S43
11. Chapman-Shimshoni D., Yuklea M., Radnay J., Shapiro H., Lishner M.: Simvastatin induced apoptosis of B-CLL by activation of mitochondrial caspase 9. Exp. Hematol., 2003; 31: 779-783
12. Corsini A. Bellosta S., Baetta R., Fumagalli R., Paoletti R., Bernini F.: New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol. Therapeut., 1999; 84: 413-428
13. Denoyelle C., Albanese P., Uzan G., Hong L., Vannier J.P., Soria J., Soria C.: Molecular mechanism of the anti-cancer activity of crivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells. Cell Signal., 2003; 15: 327-338
14. Denoyelle C., Vasse M., Körner M., Mishal Z., Ganné F., Vannier J.P., Soria J., Soria C.: Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis, 2001; 22: 1139-1148
15. Dimitroulakos J., Ye L.Y., Benzaquen M., Moore M.J., Kamel-Reid S., Freedman M.H., Yeger H., Penn L.Z.: Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatininduced apoptosis: therapeutic implications. Clin. Cancer Res., 2001; 7: 158-167
16. Duncan R.E., El-Sohemy A., Archer M.C.: Mevalonate promotes growth of tumors derivated from human cancer cells in vivo and stimulates proliferation in vitro with enhanced cyclin-dependent kinase-2 activity. J. Biol. Chem., 2004; 279: 33079-33084
17. Duncan R.E., Lau D., EL-Sohemy A., Archer M.C.: Geraniol and β-ionone inhibit proliferation, cell cycle progression, and cyclin-dependent kinase 2 activity in MCF-7 breast cancer cells independent of effects on HMG-CoA reductase activity. Biochem. Pharmacol., 2004; 68: 1739-1747
18. Endo A., Hasumi K., Negishi S.: Monacolins J and L, new inhibitors of cholesterol biosynthesis produced by Monascus ruber. J. Antibiot., 1985; 38: 420-422
19. Endo A., Kuroda M., Tsujita Y.: ML-236A, ML-236B and ML-236C, New inhibitors of cholesterogenesis produced by Penicillium citrinum. J. Antibiot., 1976; 29: 1346-1348
20. Farina H.G., Bublik D.R., Alonso D.F., Gomez D.E.: Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells. Clin. Exp. Metastasis., 2002; 19: 551-559
21. Feleszko W., Mynarczuk I., Nowis D.: Correspondence in vitro antitumor activity of cerivastatin, a novel and potent HMG-CoA reductase inhibitor. Febs. Lett., 2001; 503: 219-220
22. Feleszko W., Zagodon R., Gob J., Jakóbisiak M.: Potentiated antitumor effects of cisplatin and lovastatin against MmB16 melanoma in mice. Eur. J. Cancer, 1999; 34: 406-411
23. Feng C., Ye C., Liu X., Ma H., Li M.: b4 integrin in statin-induced endothelial cell death. Biochem. Biophys. Res. Commun., 2004; 323: 858-864
24. Fernandez C., Lobo M., Gomez-Coronado D., Lasuncion M.A.: Cholesterol is essential for mitosis progression and its deficiency induces poliploid cell formation. Exp. Cell. Res., 2004; 300: 109-120
25. Fromigue O., Hay E., Modrowski D., Bouvet S., Jacquet A., Auberger P., Marie P.J.: RhoA GTPase inactivation by statins induces osteosarcoma cell apoptosis by inhibition p42/p44-MAPKs-Bcl-2 signaling independently of BMP-2 and cell differentiation. Cell Death Differ., 2006; 13, 1845-1856
26. Graaf M.R., Richel D.J., Van Noorden C.J., Guchelaar H.J.: Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat. Rev., 2004; 30: 609-641
27. Hohl R. Larson R.A., Mannickarottu V., Yachnin S.: Inhibition of hydroxymethyl-glutaryl coenzyme A reductase activity induces a paradoxical increase in DNA synthesis in myeloid leukemia cells. Blood, 1991; 77: 1064-1070
28. Holmberg M., Sandberg C., Nygren P., Larsson R.: Effects of lovastatin on a human myeloma cell line: increased sensitivity of a multidrug-resistant subline that expresses the 170 kDa P-glycoprotein. Anti-Cancer Drug, 1994; 5: 598-600
29. Inano H., Suzuki K., Onoda M., Wakabayashi K.: Anti-carcinogenic activity of simvastatin during the promotion phase of radiationinduced mammary tumorigenesis of rats. Carcinogenesis., 1997; 18: 1723-1727
30. Jakóbisiak M., Bruno S., Skierski J.S., Darzynkiewicz Z.: Cell cycle-specific effects of lovastatin. Proc. Natl. Acad. Sci. USA, 1991; 88: 3628
31. Jani J.P., Specht S., Stemmler N., Blanock K., Singh S.V., Gupta V., Katoh A.: Metastasis of B16F10 mouse melanoma inhibited by lovastatin, an inhibitor of cholesterol biosynthesis. Invasion Metastasis, 1993; 13: 314-324
32. Jones K.D., Couldwell W.T., Hinton D.R., Su Y., He S., Anker L., Law R.E.: Lovastatin induces growth inhibition and apoptosis in human malignant glioma cells. Biochem. Biophys. Res. Commun., 1994; 205: 1681-1687
33. Kamat A.M., Nelkin G.M. Atorvastatin: A potential chemopreventive agent in bladder cancer. Urology, 2005; 66: 1209-1212
34. Katz M.S., Minsky B.D., Saltz L.B., Riedel E., Chessin D.B., Guillem J.G.: Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer. Int. J. Radiat. Oncol. Biol. Phys., 2005; 62: 1363-1370
35. Keyomarsi K., Sandoval L., Band V., Pardee A.B.: Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res., 1991; 51: 3602-3609
36. Kim J.S., Pirnia F., Choi Y.H., Nguyen P.M., Knepper B., Tsokos M., Schulte T.W., Birrer M.J., Blagosklonny M.V., Schaefer O., Mushinski J.F., Trepel J.B.: Lovastatin induces apoptosis in a primitive neuroectodermal tumor cell line in association with RB down-regulation and loss of the G1 checkpoint. Oncogene, 2000; 19: 6082-6090
37. Kimura K., Komagata D., Murakawa S., Endo A.: Biosynthesis of monacolins: conversion of monacolin J to monacolin K (mevinolin). J. Antibiot., 1990; 43: 1621-1622
38. Knox J.J., Siu L.L., Chen E., Dimitroulakos J., Kamel-Reid S., Moore M.J., Chin S., Irish J., LaFramboise S., Oza A.M.: A phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix. Eur. J. Cancer, 2005; 41: 523-530
39. Kodach L.L., Bleuming S.A., Peppelenbosch M.P., Hommes D.W., Van den Brink G.R., Hardwick J.C.: The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway. Gastroenterology, 2007; 133: 1272-1281
40. Konstantinopolous P.A., Papavassiliou A.G.: Multilevel modulation of mevalonate and protein-prenylation circuitries as a novel strategy for anticancer therapy. Trends Pharmacol. Sci., 2006; 28: 6-13
41. Kooman E.R., Joosse A., Herings R.M., Casparie M.K., Bergman W., Nijsten T., Guchelaar H.J.: Is statin use association with a reduced incidence, a reduced Breslow thickness or delayed metastasis of melanoma of the skin? Eur. J. Cancer, 2007; 43: 2580-2589
42. Koyuturk M., Ersoz M., Altiok N.: Simvastatin induces proliferation inhibition and apoptosis in C6 glioma cells via c-jun N-terminal kinase. Neurosci. Lett., 2004; 370: 212-217
43. Kumar B., Cole W.C., Prasad K.N.: Alpha tocopheryl succinate, retinoic acid and polar carotenoids enhanced the growth-inhibitory effect of a cholesterol-lowering drug on immortalized and transformed nerve cells in culture. J. Am. Coll. Nutr., 2001; 20: 628-636
44. Lamprecht J. Wójcik C., Jakóbisiak M., Stoehr M., Schrorter D., Paweletz N.: Lovastatin induces mitotic abnormalities in various cell lines. Cell Biol. Int., 1999; 23: 51-60
45. Laws P.E., Spark J.I., Cowled P.A., Fitridge R.A.: The role of statins in vascular disease. Eur. J. Vasc. Endovasc. Surg., 2004; 27: 6-16
46. Lee J., Lee I., Park C., Kang W.K.: Lovastatin-induced Rho A modulation and its effect on senescence in prostate cancer cells. Biochem. Biophys. Res. Commun., 2006; 339: 748-754
47. Lev S., Gilburd B., Lahat N., Shoenfeld Y.: Prevention of tumor spread by matrix metalloproteinase-9 inhibition: old drugs, new concept. Eur. J. Intern. Med., 2002; 13: 101-103
48. Lewis K.A., Holstein S.A., Hohl R.J.: Lovastatin alters the isoprenoid biosynthetic pathway in acute myelogenous leukemia cells in vivo. Leuk. Res., 2005; 29: 527-533
49. Li H.Y., Appelbaum F.R., Willman C.L., Zager R.A. and Banker D.E.: Cholesterol modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood, 2003; 101: 3628-3634
50. Liekens S., Clercq E. Neyts J.: Angiogenesis: regulators and clinical applications. Biochem. Pharmacol., 2001; 61: 253-270
51. López-Aquilar E., Sepúlveda-Vildósola A.C., Rivera Márquez H., Cerecedo-Diaz F., Valdez-Sánchez M., Villasis-Keever M.A.: Security and maximal tolerated doses of fluvastatin in pediatric cancer patients. Arch. Med. Res., 1998; 16: 128-131
52. Luan Z., Chase A.J., Newby A.C.: Statins inhibit secretion of metalloproteinases-1,-2,-3, and-9 from vascular smooth muscle cells and macrophages. Arterioscler. Thromb. Vasc. Biol., 2003; 23: 769-775
53. Mach F.: Statins as immunomodulators. Transpl. Immunol., 2002; 9: 197-200
54. Manzoni M., Bergomi S., Cavazzoni V.: Production of statins by filamentous fungi. Biotechnol. Lett., 1999; 21: 253-257
55. Manzoni M., Rollini M.: Biosynthesis and biotechnological production of statins by filamentous fungi and application of these cholesterol-lowering drugs. Appl. Microbiol. Biotechnol., 2002; 58: 555-564
56. Marcelli M., Cunningham G.R., Haidacher S.J., Padayatty S.J., Sturgis L., Kagan C., Denner L.: Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP. Cancer Res., 1998; 58: 76-83
57. Matar P., Rozados V.R., Binda M.M., Roggero E.A., Bonfil R.D., Scharovsky O.G.: Inhibitory effect of Lovastatin on spontaneous metastases derived from a rat lymphoma. Clin. Exp. Metastasis, 1999; 17: 19-25
58. McCarty M.F.: Suppression of dolichol synthesis with isoprenoids and statins may potentiate the cancer-retardant efficacy of IGF-1 down-regulation. Med. Hypotheses, 2001; 56: 12-16
59. McCarty M.F.: Current prospects for controlling cancer growth with non-cytotoxic agents-nutriens, phytochemicals herbal extracts, and available drugs. Med. Hypotheses, 2001; 56: 137-154
60. Mehta N., Hordines J., Volpe C., Doerr R., Cohen S.A.: Cellular effects of hypercholesterolemia in modulation of cancer growth and metastasis: A review of the evidence. Surg. Oncol., 1997; 6: 179-185
61. Merajver S.D., Usmani S.Z.: Multifaceted role of Rho proteins in angiogenesis. J. Mammary Gland Biol. Neoplasia, 2005; 10: 291-298
62. Mistafa O., Högberg J., Stenius U.: Statins and ATP regulate nuclear pAkt via the P2X7 purinergic receptor in epithelial cells. Biochem. Biophys. Res. Commun., 2008; 365: 131-136
63. Miura S., Matsuo Y., Saku K.: Simvastatin supresses coronary artery endothelial tube formation by disrupting Ras/Raf/ERK. Atherosclerosis, 2004; 175: 235-243
64. Moghadasian M.H.: Clinical pharmacology of 3-hydroxy-3-methylglutaryl Coenzyme A reductase inhibitors. Life Sci., 1999; 65: 1329-1337
65. Morris T.J., Palm S.L., Furcht L.T., Buchwald H.: The effect of lovastatin on3H thymidine uptake in HTC-4 and LLC-L1 tumor cells. J. Surg. Res., 1996; 61: 367-372
66. Moyad M.A.: Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: part II. Urol. Oncol., 2004; 22: 472-477
67. Moyad M.A., Merrick G.S., Gregory S., Mark A.: Statins and cholesterol lowering after a cancer diagnosis: Why not? Urol Oncol, 2005; 23: 49-55
68. Mueck A.O., Seeger H., Wallwiener D.Z.: Effect of statins combined with estradiol on the proliferation of human receptor-positive and receptor-negative breast cancer cells. Menopause, 2003; 10: 332-336
69. Müller C., Bockhorn A.G., Klusmeier S., Kiehl M., Roeder C., Kalthoff H., Koch O.M.: Lovastatin inhibits proliferation of pancreatic cancer cell lines with mutant as well as with wild-type K-ras oncogene but has different effects on protein phosphorylation and induction of apoptosis. Int. J. Oncol., 1998; 12: 717-723
70. Murray S.S., Tu K.N., Young K.L., Murray E.J.: The effects of lovastatin on proteasome activities in highly purified rabbit 20 S proteasome preparations and mouse MC3T3-E1 osteoblastic cells. Metabolism. 2002; 51: 1153-1160
71. Nagase H.: Activation mechanisms of matrix metalloproteinases. Biol. Chem., 1997; 378: 151-160
72. Nagase H., Woessner J.F.: Matrix metalloproteinases. J. Biol. Chem., 1999; 274: 21491-21494
73. Nelson A.R., Fingelton B., Rothenberg M.L., Matrisian L.M.: Matrix metalloproteinases: biologic activity and clinical implications. J. Clin. Oncol., 2000; 18: 1135-1149
74. Newman A., Clutterbuck R.D., Powles R.L., Catovsky D., Millar J.L.: A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal bone marrow progenitors. Leuk. Lymphoma, 1997; 24: 533-537
75. Newman A., Clutterbuck R.D., Powles R.L., Millar J.L.: Selective inhibition of primary acute myeloid leukaemia cell growth by lovastatin. Leukemia, 1994; 8: 2023-2029
76. Nübel T., Dippold W., Kleinert H., Kaina B., Fritz G.: Lovastatin inhibits rho regulated expression of E selectin by TNF a and attenuates tumor cell adhesion. FASEB J., 2004; 18: 140-142
77. Okopieñ B.: Nowe spojrzenia na plejotropowe efekty dziaania statyn. Czynnik Ryzyka, 2003; 2-4: 5-13
78. Otsuki T., Sakaguchi H. Hatayama T., Fujii T., Tsujioka T., Sugihara T., Takata A., Hyodoh F., Eto M.: Effects of an HMG-CoA reductase inhibitor, simvastatin on human myeloma cells. Oncol. Rep., 2004; 11: 1053-1058
79. Pérez-Sala D., Mollinedo F.: Inhibition of isoprenoid biosynthesis induces apoptosis in human promyelocytic HL-60 cells. Biochem. Biophys. Res. Commun., 1994; 199: 1209-1215
80. Platz E.A., Leitzmann M.F., Visvanathan K.R., Rimm E.B., Stampfer M.J., Willett W.C., Giovannucci E.: Statin drugs and risk of advanced prostate cancer (PC). J. Natl. Cancer Inst., 2006; 98: 1819-1825
81. Quesney-Huneeus V., Wiley M.H., Siperstein M.D.: Esential role for mevalonate synthesis in DNA replication. Proc. Natl. Acad. Sci. USA, 1979; 76: 5056-5060
82. Rao S., Porter D.C., Chen X., Herliczek T., Lowe M., Keyomarsi K.: Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc. Natl. Acad. Sci. USA, 1999; 96: 7797-7802
83. Rasmussen L.M., Hansen P.R., Nabipour M.T, Olesen P., Kristiansen M.T., Ledet T.: Diverse effects of inhibition of 3-hydrocy-3-methylglutaryl-CoA reductase on the expression of VCAM-1 and E-selectin in endothelial cells. Biochem. J., 2001; 360; 363-370
84. Rezaie-Majd A., Prager G.W., Bucek R.A., Schernthaner G.H., Maca T., Kress H., Valent P., Binder B.R., Minar E., Baghestanian M.: Simvastatin reduces the expression of adhesion molecules in circulating monocytes from hypercholesterolemic patiens. Arterioscler. Thromb. Vasc. Biol., 2003; 23: 397-403
85. Ridley A.J.: The GTP-binding Protein Rho. Int. J. Biochem. Cell Biol., 1997; 29: 1225-1229
86. Rubins J.B., Greatens T., Kratzke R.A., Tan A.T., Polunovsky V.A., Bitterman P.: Lovastatin induces apoptosis in malignant mesothelioma cells. Am. J. Respir. Crit. Care Med., 1998; 157: 1616-1622
87. Schmidmaier R., Baumann P., Simsek M., Dayyani F., Emmerich B., Mienhardt G.: The HMG-CoA reductase inhibitor simvastatin overcome cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase. Blood, 2004; 104: 1825-1832
88. Seeger H., Wallwiener D., Mueck A.O.: Statins can inhibit proliferation of human breast cancer cells in vitro. Exp. Clin. Endocrinol. Diabetes, 2003; 111: 47-48
89. Shipman C.M., Croucher P.I., Russel R.G., Helfrich M.H., Rogers M.J.: The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro inhibiting the mevalonate pathway. Cancer Res., 1998; 58: 5294-5297
90. Silvestris D.L., Cafforio P., Tucci M., del Prete A., Dammacco F.: VEINCTR-N, an immunogenic epitope of Fas (CD95/APO-I), and soluble Fas enhance T-cell apoptosis in vitro. II. Functional analysis and possible implications in HIV-1 disease. Mol. Med., 2000; 6: 509-526
91. Sleijfer S., Van der Gaast A., Planting A.S., Stoter G., Verweij J.: The potential of statins as part of anti-cancer treatment. Eur. J. Cancer, 2005; 41: 516-522
92. Sutter A.P., Maaser K., Höpfner M. Höpfner A., Schuppan D., Scherübl H.: Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor. J. Hepatol., 2005; 43: 808-816
93. Toledano J.E., Partridge N.C.: Statins: Not just for cholesterol? Trends Endocrinol. Metab., 2000; 11: 255-256
94. van de Donk N.W., Kamphuis M.M., van Kessel B., Lokhorst H.M., Bloem A.C.: Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels. Blood, 2003; 102: 3354-3362
95. Vaughan C.J., Gotto A.M., Basson C.T.: The evolving role of statins in the management of atherosclerosis. J. Am. Coll. Cardiol., 2000; 35: 1-10
96. Velho J.A., Okanobo H., Degasperi G.R., Matsumoto M.Y., Alberici L.C., Cosso R.D., Oliveira H.C., Vercesi A.E.: Statins induce calciumdependent mitochondrial permeability transition. Toxicology, 2006; 219: 124-132
97. Vincent L., Chen W., Hong L., Mirshahi F., Mishal Z., Mirshahi Khorassani T., Vannier J.P., Soria J., Soria C.: Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect. FEBS Lett., 2001; 495: 159-166
98. Walter A., Reuter C., Fraunberger P., Seidel D., Walli A.K.: Hypocholesterolemia in cancer. Artheriosclerosis, 2000; 151: 319
99. Wang I.K., Lin-Shiau S.Y., Lin J.K.: Suppression of invasion and MMP-9 expression in NIH 3T3 and v-H-Ras 3T3 fibroblasts by lovastatin through inhibition of ras isoprenylation. Oncology, 2000; 59: 245-254
100. Wang M., Xie Y., Girnita L., Nilsson G., Dricu A., Wejde J., Larsson O.: Regulatory role of mevalonate and N-linked glycosylation in proliferation and expression of the EWS/FLI-1 fusion protein in ewing's sarcoma cells. Exp. Cell Res., 1999; 248: 38-46
101. Wang W., Collie-Duguid E., Cassidy J.: Cerivastatin enhances cytotoxicity of 5-fluorouracil on chemosensitive and resistant colorectal cancer cell lines. FEBS Lett., 2002; 531: 415-420
102. Wang W., Macaulay R.J.: Mevalonate prevents lovastatin-induced apoptosis in medulloblastoma cell lines. Can. J. Neurol. Sci., 1999; 26: 305-310
103. Weber W.: Drug firm withdraws statins from the market. Lancet, 2001; 358: 568
104. Weitz-Schmidt G.: Statins as anti-inflammatory agents. Trends Pharmacol. Sci., 2002; 23: 482-486
105. Wong B., Lumma W.C., Smith A.M., Sisko J.T., Wright S.D., Cai T.Q.: Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation. J. Leukoc. Biol., 2001; 69: 959-962
106. Wong W., Dimitroulakos J., Minden M.D., Penn L.Z.: HMG-CoA reductase inhibitors and malignant cell: The statin family of drugs as triggers of tumor-specific apoptosis. Leukemia, 2002; 16: 508-519
107. Wong W.W., Tan M.M., Xia Z., Dimitroulakos J., Minden M.D., Penn L.Z.: Cerivastatin triggers tumor-specific apoptosis with higher effi-cacy than lovastatin. Clin. Cancer Res., 2001; 7: 2067-2075
108. Wójcik C., Bury M., Stoklosa T., Giermasz A., Feleszko W., Młynarczuk I., Pleban E., Basak G., Omura S., Jakóbisiak M.: Lovastatin and simvastatin are modulators of the proteasome. Int. J. Biochem. Cell. Biol., 2000; 32: 957-965
109. Xia Z., Tan M.M., Wong W.W., Dimitroulakos J., Minden M.D., Penn L.Z.: Blocking protein geranylgeranylation is essential for lovastatininduced apoptosis of human acute myeloid leukemia cells. Leukemia, 2001; 15: 1398-1407
110. Zhong W.B., Wang C.Y., Chang T.C., Lee W.S.: Lovastatin induces apoptosis of anaplastic thyroid cancer cells via inhibition of protein geranylgeranylation and de novo protein synthesis. Endocrinology, 2003; 14: 3852-3859